• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Saturday, July 11, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News

Hepatocellular carcinoma: Resection vs. transplantation

Bioengineer by Bioengineer
September 8, 2017
in Science News
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

COLOGNE. Liver transplantation is the gold standard for treating early hepatocellular cancers. Because of the lack of donors, this option is, however, available to a limited degree only. Curative liver resection is an alternative in this setting. Markus B. Schoenberg, Julian N. Bucher, and coauthors investigated whether liver resection (LR) can yield results that are comparable to those of liver transplantation (LT) (Dtsch Arztebl Int 2017; 114: 519-26).

The authors conducted a meta-analysis of all available studies that compared LT and LR. From the published studies, they analyzed a subgroup consisting of patients with earlier hepatocellular carcinoma (HCC) in compensated cirrhosis, for which LR as well as LT would have been an option. 54 studies including 13 794 patients were included in the subgroup analysis. In this patient population, the researchers compared overall survival after 1, 3, and 5 years, as well as morbidity and mortality in LR and LT.

In patients with early HCC, LT yielded a higher survival rate than LR only after 5 years (66.67% versus 60.35%). After 1 and 3 years the differences did not reach significance. No significant difference in terms of morbidity and mortality was seen in this subgroup.

The researchers concluded that LR in early HCC provides comparably good survival and similar complication rates compared with LT for up to 3 years. Resection should be the objective if the conditions are met. In case of a recurrence, such patients can still be evaluated for transplantation. This strategy could improve the allocation of donor livers. To enable risk stratification, the therapeutic options for the patients should be discussed in a multidisciplinary setting in specialized tumor boards.

###

https://www.aerzteblatt.de/pdf.asp?id=192677

Media Contact

Dr. Markus Rentsch
[email protected]

http://www.aerzteblatt-international.de/int/

http://dx.doi.org/10.3238/arztebl.2017.0519

Share12Tweet8Share2ShareShareShare2

Related Posts

TP53 Mutation Triggers CD8+ T Cell Exhaustion Causing Therapy-Resistant Urothelial Cancer

July 11, 2026
Transient Simulation Advances in Bioresorbable Flexible Electronic Circuits

Transient Simulation Advances in Bioresorbable Flexible Electronic Circuits

July 11, 2026

Evaluating Geriatric Assessment and Interventions for Prostate Cancer Patients on ADT

July 11, 2026

Single-Cell Multi-Omics Reveals Cancer-Associated Fibroblast Programs in Breast Cancer

July 11, 2026
Please login to join discussion

POPULAR NEWS

  • Detection of EDCs in Breast Milk and Infant Urine Up to Six Months Highlights Early Exposure Risks

    77 shares
    Share 31 Tweet 19
  • New Drug Candidate Developed at McMaster Shows Potential for Treating Brain Cancer

    58 shares
    Share 23 Tweet 15
  • KTU Researchers Explore Ultrasound’s Role in Enhancing Blood Flow Beyond Diagnostics

    53 shares
    Share 21 Tweet 13
  • 高齢者の骨粗鬆症治療の持続性比較

    51 shares
    Share 20 Tweet 13

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

TP53 Mutation Triggers CD8+ T Cell Exhaustion Causing Therapy-Resistant Urothelial Cancer

Transient Simulation Advances in Bioresorbable Flexible Electronic Circuits

Evaluating Geriatric Assessment and Interventions for Prostate Cancer Patients on ADT

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 85 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.